AttendMe Owl Logo
AttendMe
Evidence Evolution
RheumatologyRheumatology

How This Evidence Evolved

Axial Spondyloarthritis Treatment

From NSAIDs to biologics and JAK inhibitors across the radiographic spectrum

20.5

Timeline

ATLAS
2006
ABILITY-1
2013
MEASURE 1/2
2015
SELECT-AXIS 1
2019
ACR/SAA/SPARTAN
2019
ASAS-EULAR 2022 update (published 2023)
2023
Ahmed et al. (2024 review): JAK inhibitor safety in axSpA
2024
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

ATLAS tested adalimumab against placebo in active ankylosing spondylitis. At week 12, ASAS20 response occurred in 58.2% versus 20.6% (P<0.001). The report also found partial remission in 22.1% versus 5.6% (P<0.001). The trial showed that TNF-targeted therapy could improve disease activity, with adverse events reported in 75.0% versus 59.8%, but no significant infection difference.
Proof

Landmark RCTs and pivotal trials that established the evidence base

ABILITY-1 evaluated adalimumab in non-radiographic axSpA with inadequate response, intolerance or contraindication to NSAIDs. ASAS40 at week 12 was 36% versus 15% with placebo (P<0.001). MEASURE 1 and 2 tested secukinumab, an IL-17A inhibitor, in ankylosing spondylitis. In MEASURE 2, which included 219 patients, secukinumab 150 mg achieved ASAS20 in 61% versus 28% with placebo at week 16 (P<0.001). These trials demonstrate efficacy in their defined populations without establishing a treatment sequence after TNF failure.
Extension

Follow-up studies, subgroup analyses, and real-world validation

SELECT-AXIS 1 tested oral upadacitinib 15 mg daily in biologic-naive adults with active ankylosing spondylitis and inadequate response, intolerance or contraindication to NSAIDs. Among 187 randomized patients, ASAS40 at week 14 was 52% versus 26% with placebo (P=0.0003). This supports JAK1 inhibition as a treatment option in that population; it does not directly compare upadacitinib with TNF or IL-17 inhibitors.
Guidelines

Integration into clinical practice guidelines and recommendations

ASAS-EULAR 2022 uses NSAIDs first; TNF/IL-17/JAK options require ASDAS ≥2.1 after ≥2 NSAIDs plus elevated CRP, sacroiliac MRI inflammation or radiographic sacroiliitis. Current practice starts TNF/IL-17. ACR/SAA/SPARTAN 2019 conditionally prefers TNFi as first biologic and IL-17i after primary TNFi nonresponse. Both address AS and nr-axSpA. JAK inhibitors (upadacitinib, tofacitinib) are included as options. A 2024 review advises caution and shared decisions; the cardiovascular and malignancy risks seen in higher-risk RA populations remain uncertain in axSpA.
ASAS-EULAR 2022 update (published 2023)

NSAIDs first; TNF/IL-17/JAK options require ASDAS ≥2.1 after ≥2 NSAIDs and one of: elevated CRP, sacroiliac MRI inflammation or radiographic sacroiliitis.

ACR/SAA/SPARTAN

Adults with active axSpA despite NSAIDs: conditional TNFi preference over IL-17i; primary TNFi nonresponse: conditional secukinumab/ixekizumab over another TNFi.

Now

Current standard of care and ongoing research directions

The cited randomized studies evaluate adalimumab, secukinumab and upadacitinib in distinct populations. ABILITY-1 supports adalimumab in non-radiographic axSpA: ASAS40 at week 12 was 36% versus 15% with placebo (P<.001). MEASURE and SELECT-AXIS 1 studied ankylosing spondylitis; these reports do not establish availability of every class across both disease categories. How should comparative trials inform selection after NSAID intolerance or inadequate response? Can early therapy prevent structural progression, and what evidence would justify combining targeted treatments?

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Which targeted treatments were studied in ankylosing spondylitis?+
The supplied randomized evidence covers adalimumab (ATLAS: ASAS20 58.2% versus 20.6% placebo at week 12), secukinumab (MEASURE 2: ASAS20 61% versus 28% at week 16), and upadacitinib (SELECT-AXIS 1: ASAS40 52% versus 26% at week 14). ABILITY-1 and SELECT-AXIS 1 allowed NSAID intolerance or contraindication as well as inadequate response; prior failure is not the only qualifying circumstance.
Can non-radiographic axial spondyloarthritis be treated with biologics?+
The ABILITY-1 trial established adalimumab efficacy in non-radiographic axial spondyloarthritis after inadequate response, intolerance or contraindication to NSAIDs: ASAS40 response at week 12 was 36% versus 15% with placebo (p<0.001). The cited secukinumab and upadacitinib trials studied ankylosing spondylitis. Their findings should be distinguished from the non-radiographic population in ABILITY-1.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026